S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P’s upgrade to BBB- gives Teva investment-grade status across all major rating agencies, supporting future financing and growth plans.

Rhea-AI Summary

Teva (TEVA) announced that S&P Global Ratings upgraded its long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With earlier upgrades from Fitch and Moody’s, Teva now holds investment-grade ratings from all agencies that cover its debt, which the company says reflects strong execution, debt reduction and improved financial flexibility.

Positive

• S&P rating upgrade to BBB- from BB+ with Stable outlook
• Teva now holds investment-grade credit ratings from all agencies covering its debt
• Management links the upgrades to debt reduction and a stronger financial profile
• Company highlights enhanced financial flexibility to invest in growth

Negative

• None.

Market Context

TEVA closed at $36.62 before publication, while UTHR was down 0.78% in current peer data. That compa...

Analysis

TEVA closed at $36.62 before publication, while UTHR was down 0.78% in current peer data. That comparison adds market context to the upgrade; insider net selling remains a risk, and execution warrants attention.

Key Figures

S&P credit rating: BBB- Rating upgrades: 3 upgrades

2 metrics

S&P credit rating BBB- Long-term issuer credit rating, upgraded from BB+

Rating upgrades 3 upgrades S&P, Fitch and Moody’s in recent months

Historical Context

5 past events · Latest: Sep 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 02	Phase 2a clinical data	Positive	+3.5%	Positive topline results met the primary endpoint with statistically significant findings.
Sep 01	Investor conference schedule	Neutral	+3.5%	Teva scheduled presentations at three September investor conferences.
Aug 31	U.S. policy discussions	Neutral	+0.4%	Teva announced discussions on affordable medicines and supply chain security.
Aug 28	Neuroscience asset acquisition	Positive	-3.1%	Teva proposed acquiring BXCL501 rights with upfront and contingent payments.
Aug 19	Priority review acceptance	Positive	+2.5%	FDA accepted ecopipam's NDA and granted Priority Review.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and regulatory announcements had positive historical reactions, while strategic or preliminary corporate news showed mixed or divergent responses.

Key Terms

long-term issuer credit rating, investment-grade credit ratings, biosimilars, late-stage assets

4 terms

long-term issuer credit rating financial

"S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating"

A long-term issuer credit rating is an independent assessment of an organization’s ability to repay its debts over several years, like a report card that summarizes how likely it is to meet loan and bond obligations beyond the short term. Investors use it to judge risk and expected returns: higher ratings usually mean lower borrowing costs and safer bond investments, while lower ratings signal greater default risk, similar to choosing whether to lend money to a careful neighbor or a risky one.

investment-grade credit ratings financial

"Teva now has investment-grade credit ratings from all the agencies"

A classification by major credit rating agencies that marks a bond or issuer as having relatively low risk of default; investment-grade ratings are those at or above the agencies' minimum “safe” thresholds (for example, BBB− or higher from S&P/Fitch or Baa3 or higher from Moody’s). It matters to investors because the rating acts like a credit score for a borrower, influencing demand, the interest rate issuers must pay, and which funds or institutional mandates can hold the security.

biosimilars medical

"providing complex generic medicines, biosimilars and pharmacy brands worldwide"

Biosimilars are medicines made to be highly similar to an already approved biological drug produced from living cells, with no meaningful differences in safety or effectiveness. They matter to investors because they introduce lower‑cost competition to expensive biologic treatments—similar to how generic drugs compete with brand drugs—but involve more complex manufacturing, regulatory review and patent risk, which can affect market share, pricing and profit margins across the sector.

late-stage assets technical

"its pipeline of significant late-stage assets"

Late-stage assets are products, drug candidates, or business projects that have reached the final phases of development before regulatory approval or commercial launch — for example, clinical programs in pivotal trials or products with completed testing awaiting approval. They matter to investors because they are closer to generating revenue or definitive regulatory outcomes, so their value typically hinges on near-term clinical results, regulatory decisions, or launch-readiness rather than early research milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With this upgrade, along with the other recent upgrades from Fitch and Moody’s, Teva now has investment-grade credit ratings from all the agencies which cover its debt.

Eli Kalif, Teva's Chief Financial Officer, commented: “Teva’s trio of rating upgrades in just a few months reflects the strong execution of our Pivot to Growth strategy and the meaningful progress we have made in reducing debt and strengthening our financial profile. This significant milestone further enhances our financial flexibility to invest in growth and deliver long-term value.”

S&P’s report highlights Teva’s sustainable growth prospects through its strong execution in branded products, its stabilization in generics, and its pipeline of significant late-stage assets.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to continue and improve our financial ratings; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; compliance, regulatory and litigation matters; financial, economic and other risks; and other factors discussed in this Press Release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries:  TevaCommunicationsNorthAmerica@tevapharm.com 

Teva Investor Relations Inquiries:   TevaIR@Tevapharm.com

 

FAQ

What credit rating upgrade did S&P Global Ratings announce for Teva (TEVA)?

S&P Global Ratings upgraded Teva’s long-term issuer credit rating to BBB- from BB+ and assigned a Stable outlook. This moves Teva into investment-grade territory at S&P.

Does Teva (TEVA) now have investment-grade credit ratings from all major agencies?

Yes. With S&P’s upgrade to BBB- and earlier upgrades from Fitch and Moody’s, Teva now has investment-grade credit ratings from all agencies that cover its debt.

How many credit rating upgrades has Teva (TEVA) received in recent months?

Teva reports a “trio of rating upgrades” in just a few months, including the latest S&P move to BBB- and earlier upgrades from Fitch and Moody’s to investment-grade levels.

What reasons are given for S&P’s credit rating upgrade of Teva (TEVA)?

S&P’s report highlights Teva’s sustainable growth prospects, strong execution in branded products, stabilization in generics, and a pipeline of significant late-stage assets as reasons for the improved rating.

How does Teva’s management describe the impact of the new BBB- rating on TEVA?

Teva’s CFO says the rating upgrades reflect strong execution, debt reduction, and a stronger financial profile, calling the move a “significant milestone” that enhances financial flexibility to invest in growth and support long-term value.

What does the investment-grade status mean for Teva’s (TEVA) financial profile?

Investment-grade ratings from S&P, Fitch and Moody’s indicate an improved credit risk profile. Teva states that this status enhances its financial flexibility, supporting future investment in growth initiatives and its transformation strategy.

How does the rating upgrade relate to Teva’s Pivot to Growth strategy for TEVA?

Teva’s CFO links the trio of upgrades to strong execution of the company’s Pivot to Growth strategy, which includes reducing debt and strengthening its financial profile while pursuing growth in branded products and late-stage pipeline assets.